Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. However, to invest in drug development for this condition, a number of methodological issues will need to be addressed.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

DECEMBER 28, 2022

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. But what steps can the smaller companies at the cutting edge take to make them acquisition-ready and maximise their value during this process?

Compliance 115

Compliance Regulation Manufacturing Licensing 115

pharmaphorum

JULY 5, 2021

Parexel has been a champion of the concept for years, but while adoption was fairly slow pre-COVID, it has accelerated at a fast pace since the crisis, aided by the increasing willingness of regulators to accept decentralised trial data in marketing applications.

Clinical Trials 62

Clinical Trials Clinical Trials Regulation Trials 62

pharmaphorum

OCTOBER 28, 2020

Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drug development. Identifying, recruiting, retaining and monitoring patients during this part of the cycle is estimated to cost pharma US$19 billion a year as companies seek to harvest patient experiences. The way back.

Medicine 117

Medicine Pharma Companies Vaccination Vaccine 117

pharmaphorum

JANUARY 7, 2021

The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.

Doctors 51

Doctors Doctor Immune Response Pharma Companies 51

pharmaphorum

MAY 14, 2021

Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab. Arnout Ploos van Amstel is no stranger to the cut-throat world of inflammatory disease drugs, a market that is worth billions and has spawned some of the biggest blockbusters ever.

Licensing 59

Licensing Licensing Drugs Marketing 59

pharmaphorum

NOVEMBER 30, 2022

The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e. Veeva is equally ‘super excited’.

Life Science 97

Life Science Pharma Companies Sales Marketing 97

XTalks

DECEMBER 29, 2022

For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. As of December 16, 2022, there are seven US Food and Drug Administration (FDA) approved gene therapies.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

pharmaphorum

MAY 27, 2022

Once stakeholders are confident that technologies are adequately validated, selection based on scientific and ethical considerations can be presented to regulators in accordance with applicable legal and regulatory frameworks. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials.

Clinical Trials 78

Clinical Trials Clinical Trials Trials Packaging 78

pharmaphorum

MAY 14, 2021

Long headquartered in London, the EU drug regulator is now severed from the country both physically and systematically, with its base now in Amsterdam and the UK now assessing drugs through its own regulatory agency, MHRA. The post How will NICE fare in a post-Brexit world? appeared first on.

Marketing 57

Marketing Regulation Medicine Life Science 57

pharmaphorum

DECEMBER 21, 2020

A year ago, the names Moderna and BioNTech were known mainly to those who followed biotech and pharma dealings. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccination 90

Vaccination Vaccine Doctors Doctor 90

Advarra

JULY 19, 2022

If the sponsor wants their drug approved, they need to complete all clinical studies and submit an application. Q: Please discuss the transfer of investigational new drug (IND) sponsorship from one sponsor to another and that process. The sponsor is the pharmaceutical company conducting the trial. A: No, this is not allowed.

Packaging 52

Packaging Packaging Drugs Containment 52

Drug Discovery World

MARCH 29, 2023

Politico published a summary of the key propositions outlined in the draft 2 , and DDW’s Multimedia Editor Megan Thomas investigates their intention, and observes how the industry has responded. Key proposals Approved drugs must launch in all EU countries within two years Politico described this as a measure to ensure a level playing field.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

pharmaphorum

APRIL 1, 2021

AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary. We speak to the company’s CEO and co-founder, Szabolcs Nagy, to find out why moving beyond traditional biotech drug development is a good fit for the country’s ecosystem. Hungary’s ecosystem.

Bioinformatics 104

Bioinformatics Drugs Development Scientist 104

pharmaphorum

DECEMBER 8, 2020

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The company says in its IPO prospectus that it plans to list its shares on the Nasdaq Global Market under the ABCL ticker.

Drugs 101

Drugs Antibody FDA Approval Pharma Companies 101

pharmaphorum

AUGUST 4, 2020

Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca. The company’s shares were valued as high as 95p on the London Stock Exchange following the announcement, the highest they had been since 2015.

Drugs 90

Drugs Clinical Trials Clinical Trials Pharma Companies 90

pharmaphorum

DECEMBER 7, 2020

Bureaucracy, political upheaval, and lack of regulations continue to make Latin America a difficult market for European and North American pharma to enter – and COVID-19 has only worsened these issues. For example, price regulations are becoming more common in Latin America, often being based on models such as NICE’s.

Marketing 89

Marketing Regulation Production Medicine 89

pharmaphorum

MAY 21, 2021

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs reformulated to provide extra benefits for patients. . We have been well known within pharma with the tech platform that can deliver. “We

Insulin 52

Insulin Drugs Production Marketing 52

pharmaphorum

SEPTEMBER 1, 2020

Another military man in the drugs business was Edward Robinson Squibb, who as a naval doctor during the Mexican-American war of 1846–1848 threw the drugs he was supplied with overboard due to their low quality. This investment fuelled the development of drugs to come over the coming decades.

Medicine 145

Medicine Insulin Pharmacy Drugs 145

pharmaphorum

MAY 26, 2022

While many pharma companies are actively working on initiatives to improve diversity in clinical trials, we still have a long way to go. A risk-benefit approach underpins the decision-making process to evaluate human drugs, drug/device combinations and advanced therapy medicinal products for licensing of human medicines.

Clinical Trials 139

Clinical Trials Clinical Trials Trials Medicine 139

Pharmaceutical Technology

AUGUST 12, 2022

In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.

Medicine 290

Medicine Production Generic Drugs Regulation 290

The Pharma Data

NOVEMBER 5, 2020

The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect,” says Anna Ljung, CEO of Moberg Pharma. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 CET on November 6, 2020.

Marketing 40

Marketing Production Regulation Containment 40

XTalks

MARCH 22, 2023

To celebrate this milestone, we’re taking a look back over the last 20 years in the pharmaceutical industry by highlighting some of the most talked-about mergers, blockbuster drugs, trends in FDA approvals and what’s next. In 2015, LabCorp acquired Covance , and Quintiles and IMS Health formed a joint venture in 2016, dubbed IQVIA.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

XTalks

SEPTEMBER 5, 2023

Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies. To address cultural considerations, it is essential that pharma companies work together with healthcare providers to promote trust in vaccines.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

The Pharma Data

DECEMBER 30, 2020

Food and Drug Administration (FDA), noted in December 2020 that he expected the pandemic could “effectively” be ended in 2021 with the launch of the Pfizer-BioNTech and Moderna vaccines. The reason for this is still not understood and many regulators may want it to be explained before authorizing it for broader use.

Vaccination 52

Vaccination Vaccine Gene Therapy Trials 52

XTalks

FEBRUARY 15, 2024

US Senator Bernie Sanders, who chairs the Health, Education, Labor, and Pensions (HELP) Committee, managed to bring CEOs of major American pharma companies to a committee hearing to discuss exorbitant US drug pricing. Scapegoating PBMs has been an industry default in trying to explain exorbitant US drug prices.

Drugs 52

Drugs Pharma Companies Pharmacy Regulation 52